Plasma MicroRNA levels are associated with Hepatitis B e antigen status and treatment response in chronic Hepatitis B patients
| Autor: | Meike H. van der Ree, R. Bart Takkenberg, Zita Kruize, Neeltje A. Kootstra, Ad C. van Nuenen, Hendrik W. Reesink, Louis Jansen, Karel A. van Dort |
|---|---|
| Přispěvatelé: | Internal medicine, Other departments, AII - Infectious diseases, APH - Aging & Later Life, Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Adult Male HBsAg Treatment response Carcinoma Hepatocellular Combination therapy medicine.disease_cause Antiviral Agents Cohort Studies 03 medical and health sciences Hepatitis B Chronic Cell Line Tumor microRNA medicine Immunology and Allergy Humans Hepatitis B e Antigens Hepatitis B virus business.industry Liver Neoplasms virus diseases Middle Aged digestive system diseases MicroRNAs 030104 developmental biology Infectious Diseases Real-time polymerase chain reaction Treatment Outcome HBeAg Viral replication Immunology Female business |
| Zdroj: | Journal of Infectious Diseases, 215(9), 1421-1429. Oxford University Press Journal of infectious diseases, 215(9), 1421-1429. Oxford University Press Van Der Ree, M H, Jansen, L, Kruize, Z, Van Nuenen, A C, Van Dort, K A, Bart Takkenberg, R, Reesink, H W & Kootstra, N A 2017, ' Plasma MicroRNA levels are associated with Hepatitis B e antigen status and treatment response in chronic Hepatitis B patients ', Journal of Infectious Diseases, vol. 215, no. 9, pp. 1421-1429 . https://doi.org/10.1093/infdis/jix140 |
| ISSN: | 0022-1899 |
| DOI: | 10.1093/infdis/jix140 |
| Popis: | Background. Hepatitis B virus (HBV) modulates microRNA (miRNA) expression to support viral replication. The aim of this study was to identify miRNAs associated with hepatitis B e antigen (HBeAg) status and response to antiviral therapy in patients with chronic hepatitis B (CHB) , and to assess if these miRNAs are actively secreted by hepatoma cells. Methods. Plasma miRNA levels were measured by reverse-transcription quantitative polymerase chain reaction in healthy controls (n = 10) and pretreatment samples of an identification cohort (n = 24) and a confirmation cohort (n = 64) of CHB patients treated with peginterferon/nucleotide analogue combination therapy. Levels of HBV-associated miRNAs were measured in cells, extracellular vesicles, and hepatitis B surface antigen (HBsAg) particles of hepatoma cell lines. Results. HBeAg-positive patients had higher plasma levels of miR-122-5p, miR-125b-5p, miR-192-5p, miR-193b-3p, and miR- 194-5p compared to HBeAg-negative patients, and levels of these miRNAs were associated with HBV DNA and HBsAg levels. Pretreatment plasma levels of miR-301a-3p and miR-145-5p were higher in responders (combined response or HBsAg loss) compared to nonresponders. miR-192-5p, miR-193b-3p, and miR-194-5p were present in extracellular vesicles and HBsAg particles derived from hepatoma cells. Conclusions. We identified miRNAs that are associated with HBeAg status, levels of HBV DNA and HBsAg, and treatment response in CHB patients. We demonstrated that several of these miRNAs are present in extracellular vesicles and HBsAg particles secreted by hepatoma cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|